Highly Endocrine Responsive Operable Breast Cancer Clinical Trial
Official title:
Letrozole as Neoadjuvant Treatment in Postmenopausal and Premenopausal Patients With Highly Endocrine Responsive Operable Breast Cancer
Verified date | September 2012 |
Source | Guangdong General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study aimed to compare the duration to complete or partial response (CR/PR) and the overall response rates (ORR) after six months of neoadjuvant endocrine therapy between pre-menopausal group and post-menopausal group with highly endocrine responsive operable mammary carcinoma.
Status | Completed |
Enrollment | 46 |
Est. completion date | July 2017 |
Est. primary completion date | July 2017 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Females =18 years 2. ER-positive (=50%), PgR-positive (=50% ), HER2-negative, and previously untreated, non-metastatic primary invasive BC. 3. The tumour size had to be >1 cm. Exclusion Criteria: 1. male patients; 2. patients with inflammatory breast cancer or distant metastasis; 3. patients who were previously treatment treated with chemotherapy, radiation therapy or prior treatment with AIs or antiestrogens for breast cancer; 4. patients with a second concomitant neoplasm; 5. patients who could not meet the eligibility criteria. |
Country | Name | City | State |
---|---|---|---|
China | Minyi Cheng | Guanzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Guangdong General Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ORR | overall response rate | six months |